Hazardous, thank you for posting this.
In a nut-shell, to me, this news is very encouraging. The key elements for me are;
1) 1 patient died = 96.42% survival rate – this is much better than Oz trails (was 83%), but again this is early days yet.
2) Serious adverse effect in 7 patients = 85% non-serious adverse effects
3) Discharge from hospital = 21 patient left hospital within 30 days = 75% NOT 66.7 as published – unless I missed something??!!
There seems to be a cross-over or unclear as to the number of patients discharged and those suffering Adverse Effect (possibly after discharge).
I am not sure what is meant by “patient had expired, while the surviving patients are still on support.”. Support could mean anything, from being on medication to being monitored? Any thoughts??
As I said, for my money, it seems very encouraging.
Cheers
- Forums
- ASX - By Stock
- VCR
- article from the hfsa conf.
VCR
ventracor limited
article from the hfsa conf., page-4
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
Currently unlisted public company.
The Watchlist
NUZ
NEURIZON THERAPEUTICS LIMITED
Dr Michael Thurn, CEO & MD
Dr Michael Thurn
CEO & MD
SPONSORED BY The Market Online